Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 4.9% - Time to Sell?

Key Points

• Taysha Gene Therapies' stock price has fallen by 4.9%, trading at around $4.53, with the volume of shares traded down by 24% compared to the average.
• Analysts have varied opinions on the stock, with nine firms issuing a "buy" rating and a consensus target price of $9.00, after several firms raised their target prices recently.
• The company reported a loss of ($0.09) EPS for the last quarter and had a negative net margin of 1,144.97%, indicating significant financial challenges.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report)'s stock price traded down 4.9% during mid-day trading on Monday . The company traded as low as $4.54 and last traded at $4.53. 2,882,384 shares were traded during mid-day trading, a decline of 24% from the average session volume of 3,802,412 shares. The stock had previously closed at $4.76.

Analyst Upgrades and Downgrades

Several research firms have weighed in on TSHA. Needham & Company LLC raised their target price on Taysha Gene Therapies from $8.00 to $10.00 and gave the company a "buy" rating in a report on Thursday. Bank of America assumed coverage on Taysha Gene Therapies in a report on Friday, July 11th. They set a "buy" rating and a $8.00 price objective on the stock. Robert W. Baird boosted their target price on Taysha Gene Therapies from $7.00 to $12.00 and gave the stock an "outperform" rating in a report on Thursday. Chardan Capital upped their target price on Taysha Gene Therapies from $9.00 to $10.00 and gave the stock a "buy" rating in a research report on Tuesday, August 12th. Finally, Wells Fargo & Company increased their price target on Taysha Gene Therapies from $7.50 to $8.00 and gave the company an "overweight" rating in a report on Wednesday, August 13th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $9.00.

Taysha Gene Therapies Trading Down 7.1%

The company has a debt-to-equity ratio of 0.17, a current ratio of 12.48 and a quick ratio of 12.48. The business has a 50-day simple moving average of $3.03 and a two-hundred day simple moving average of $2.48.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.02). The firm had revenue of $1.99 million during the quarter, compared to analyst estimates of $1.61 million. Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 78.44%. As a group, research analysts predict that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

Insider Buying and Selling at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 200,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $3.23, for a total transaction of $646,000.00. Following the completion of the sale, the insider owned 1,006,439 shares of the company's stock, valued at approximately $3,250,797.97. This trade represents a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 3.78% of the company's stock.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of hedge funds and other institutional investors have recently bought and sold shares of TSHA. Octagon Capital Advisors LP boosted its stake in Taysha Gene Therapies by 17.7% in the second quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company's stock worth $29,089,000 after purchasing an additional 1,892,500 shares in the last quarter. Jefferies Financial Group Inc. lifted its position in Taysha Gene Therapies by 4,105.3% during the 2nd quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company's stock worth $23,825,000 after buying an additional 10,068,479 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in Taysha Gene Therapies during the 2nd quarter worth about $11,178,000. Tybourne Capital Management HK Ltd. increased its position in Taysha Gene Therapies by 10.7% in the 2nd quarter. Tybourne Capital Management HK Ltd. now owns 4,095,000 shares of the company's stock valued at $9,459,000 after acquiring an additional 395,000 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Taysha Gene Therapies by 3.5% in the second quarter. Geode Capital Management LLC now owns 3,793,572 shares of the company's stock worth $8,765,000 after acquiring an additional 128,840 shares during the last quarter. 77.70% of the stock is owned by institutional investors and hedge funds.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.